323 related articles for article (PubMed ID: 22674772)
1. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies.
Rosenblat M; Ward S; Volkova N; Hayek T; Aviram M
Biofactors; 2012; 38(4):292-9. PubMed ID: 22674772
[TBL] [Abstract][Full Text] [Related]
2. HDL3 stimulates paraoxonase 1 antiatherogenic catalytic and biological activities in a macrophage model system: in vivo and in vitro studies.
Rosenblat M; Volkova N; Aviram M
Biofactors; 2014; 40(5):536-45. PubMed ID: 25230879
[TBL] [Abstract][Full Text] [Related]
3. Injection of paraoxonase 1 (PON1) to mice stimulates their HDL and macrophage antiatherogenicity.
Rosenblat M; Volkova N; Aviram M
Biofactors; 2011; 37(6):462-7. PubMed ID: 22162319
[TBL] [Abstract][Full Text] [Related]
4. Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies.
Efrat M; Rosenblat M; Mahmood S; Vaya J; Aviram M
Atherosclerosis; 2009 Feb; 202(2):461-9. PubMed ID: 18585720
[TBL] [Abstract][Full Text] [Related]
5. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
Rosenblat M; Karry R; Aviram M
Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
[TBL] [Abstract][Full Text] [Related]
6. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo.
Gugliucci A
Clin Chim Acta; 2014 Feb; 429():38-45. PubMed ID: 24280342
[TBL] [Abstract][Full Text] [Related]
7. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells.
Deakin S; Moren X; James RW
Atherosclerosis; 2005 Mar; 179(1):17-25. PubMed ID: 15721005
[TBL] [Abstract][Full Text] [Related]
8. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
9. Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL.
Gugliucci A; Kinugasa E; Ogata H; Caccavello R; Kimura S
Clin Chim Acta; 2014 Mar; 430():9-14. PubMed ID: 24384301
[TBL] [Abstract][Full Text] [Related]
10. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
Norioka M; Suzuki M; Ryomoto K; Ikebuchi M; Harano Y
J Atheroscler Thromb; 2000; 7(4):198-202. PubMed ID: 11521682
[TBL] [Abstract][Full Text] [Related]
11. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities.
Rock W; Rosenblat M; Miller-Lotan R; Levy AP; Elias M; Aviram M
J Agric Food Chem; 2008 Sep; 56(18):8704-13. PubMed ID: 18759451
[TBL] [Abstract][Full Text] [Related]
12. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.
Eisenberg S; Gavish D; Oschry Y; Fainaru M; Deckelbaum RJ
J Clin Invest; 1984 Aug; 74(2):470-82. PubMed ID: 6378975
[TBL] [Abstract][Full Text] [Related]
13. Macrophage paraoxonase 1 (PON1) binding sites.
Efrat M; Aviram M
Biochem Biophys Res Commun; 2008 Nov; 376(1):105-10. PubMed ID: 18762170
[TBL] [Abstract][Full Text] [Related]
14. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
Ikewaki K; Noma K; Tohyama J; Kido T; Mochizuki S
Int J Cardiol; 2005 Jun; 101(3):441-7. PubMed ID: 15907413
[TBL] [Abstract][Full Text] [Related]
15. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I.
Gaidukov L; Viji RI; Yacobson S; Rosenblat M; Aviram M; Tawfik DS
Biochemistry; 2010 Jan; 49(3):532-8. PubMed ID: 20025294
[TBL] [Abstract][Full Text] [Related]
16. Low high-density lipoprotein cholesterol is not responsible for decreased paraoxonase activity in chronic renal failure.
Varga É; Seres I; Harangi M; Kárpáti I; Koncsos P; Sztanek F; Paragh G
Kidney Blood Press Res; 2012; 35(4):265-72. PubMed ID: 22378349
[TBL] [Abstract][Full Text] [Related]
17. The transport of triglyceride in the high-density lipoproteins of human plasma.
Barter PJ; Connor WE
J Lab Clin Med; 1975 Feb; 85(2):260-72. PubMed ID: 163284
[TBL] [Abstract][Full Text] [Related]
18. Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.
Ushiroyama T; Sakuma K; Nosaka S
J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):142-8. PubMed ID: 16891292
[TBL] [Abstract][Full Text] [Related]
19. Lyso-DGTS lipid isolated from microalgae enhances PON1 activities in vitro and in vivo, increases PON1 penetration into macrophages and decreases cellular lipid accumulation.
Dahli L; Atrahimovich D; Vaya J; Khatib S
Biofactors; 2018 May; 44(3):299-310. PubMed ID: 29659105
[TBL] [Abstract][Full Text] [Related]
20. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
Mackness MI; Bhatnagar D; Durrington PN; Prais H; Haynes B; Morgan J; Borthwick L
Eur J Clin Nutr; 1994 Dec; 48(12):859-65. PubMed ID: 7889894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
